Sosei Heptares Receives $3.75M as a Part of its Multi-Target Agreement with Genentech

Share this

Sosei Heptares Receives $3.75M as a Part of its Multi-Target Agreement with Genentech


  • As part of the 2019 multi-target research collaboration & license agreement between Sosei Heptares & Genentech, Sosei will receive a milestone payment of $3.75M following which Genentech will be held responsible for the development & marketing of the GPCR targeting products (small molecules and/or biologics) for undisclosed therapy areas
  • As per the agreement, Sosei is eligible to receive up to ~1B as milestone payments upon achieving pr-specified research, development & commercialization events
  • The collaboration leverages Sosei’s proprietary GPCR-focused structure-based drug design capabilities along with Genentech’s discovery, development & therapeutic area expertise directed towards multiple GPCR targets selected by Genentech

Ref: Sosei Heptares | Image: Sosei Heptares

Related News:- Sosei Heptares Partner Pfizer Report the First Patient Dosing of PF-07081532 in the P-II Clinical Trial for the Treatment of Type 2 Diabetes and Obesity

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions